Project 3 has developed new approaches for targeting brain tumors using lipidic nanoparticle-based drugs, ncluding novel liposomes and immunoliposomes. These advances include: new and extremely robust technologies for drug loading and stabilization, resulting in novel nanoliposomal drugs that can deliver a number of anticancer compounds to brain tumors;antibody-targeted constructs (immunoliposomes) against EGFR and/or EGFRvlll;the first successful demonstration of convection-enhanced delivery (CED) of lipidic nanoparticles in the CMS;and imaging of drug delivery using CED of liposomal gadolinium (Gd). One of these novel agents, nanoliposomal CPT-11, has shown highly promising preclinical efficacy and has entered clinical trials as a systemic treatment. Using a clinically validated liposome-based scaffold, we can engineer additional capabilities to generate innovative and multifunctional nanoparticles for targeted delivery of anticancer drugs, either by systemic or CED routes. We now hypothesize that CED of lipidic nanoparticle- based agents combining drug delivery with imaging capability can provide targeted therapy of brain tumors. Our ongoing studies infusing lipidic nanoparticles into the brain via CED have exceeded our expectations as a robust and clinically applicable approach for the treatment of brain tumors, including the potential for targeting via MRI guidance. Accordingly, we will develop multifunctional nanoparticle-based systems for integrated image-guided therapy, combining encapsulated drugs and MRI probes and optimized for CED infusion to brain tumors.
Our Aims i nclude: 1) Develop lipidic nanoparticle/CED imaging strategy via co- infusion system or multifunctional nanoparticles co-encapsulating Gd + drug;2) Evaluate other lipidic nanoparticle agents in conjunction with image-guided CED, including other cytotoxic drugs and siRNA;3) Evaluate immunoliposome targeting combined with CED;and 4) Translate "best" multifunctional lipidic nanoparticle agent/strategy to clinical trial. Lay summary: We are studying new approaches to deliver drugs more efficiently to brain tumors using nanoparticle agents (sub-microscopic carriers of drugs). We propose to infuse these particles directly into the brain to target brain tumors, and will use MRI to guide this treatment.
|Amirian, E Susan; Scheurer, Michael E; Zhou, Renke et al. (2016) History of chickenpox in glioma risk: a report from the glioma international case-control study (GICC). Cancer Med 5:1352-8|
|Amirian, E Susan; Armstrong, Georgina N; Zhou, Renke et al. (2016) The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. Am J Epidemiol 183:85-91|
|Koestler, Devin C; Jones, Meaghan J; Usset, Joseph et al. (2016) Improving cell mixture deconvolution by identifying optimal DNA methylation libraries (IDOL). BMC Bioinformatics 17:120|
|Walsh, Kyle M; Ohgaki, Hiroko; Wrensch, Margaret R (2016) Epidemiology. Handb Clin Neurol 134:3-18|
|Phillips, Joanna J; Gong, Henry; Chen, Katharine et al. (2016) Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. Acta Neuropathol 132:757-760|
|Ladomersky, Erik; Zhai, Lijie; Gritsina, Galina et al. (2016) Advanced age negatively impacts survival in an experimental brain tumor model. Neurosci Lett 630:203-8|
|Dasgupta, Tina; Olow, Aleksandra K; Yang, Xiaodong et al. (2016) Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol 126:385-93|
|Duleh, Steve; Wang, Xianhong; Komirenko, Allison et al. (2016) Activation of the Keap1/Nrf2 stress response pathway in autophagic vacuolar myopathies. Acta Neuropathol Commun 4:115|
|Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90|
|Ojha, Juhi; Codd, Veryan; Nelson, Christopher P et al. (2016) Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia. Cancer Epidemiol Biomarkers Prev 25:1043-9|
Showing the most recent 10 out of 293 publications